Farzan, Niloufar and Vijverberg, Susanne J. and Andiappan, Anand K. and Arianto, Lambang and Berce, Vojko and Blanca-Lopez, Natalia and Bisgaard, Hans and Bonnelykke, Klaus and Burchard, Esteban G. and Campo, Paloma and Canino, Glorisa and Carleton, Bruce and Celedon, Juan C. and Chew, Fook Tim and Chiang, Wen Chin and Cloutier, Michelle M. and Daley, Denis and Den Dekker, Herman T. and Dijk, Nicole F. and Duijts, Liesbeth and Flores, Carlos and Forno, Erick and Hawcutt, Daniel B. and Hernandez-Pacheco, Natalia and de Jongste, Johan C. and Kabesch, Michael and Koppelman, Gerard H. and Manolopoulos, Vangelis G. and Melen, Erik and Mukhopadhyay, Somnath and Nilsson, Sara and Palmer, Colin N. and Pino-Yanes, Maria and Pirmohamed, Munir and Potocnki, Uros and Raaijmakers, Jan A. and Repnik, Katja and Schieck, Maximilian and Sio, Yang Yie and Smyth, Rosalind L. and Szalai, Csaba and Tantisira, Kelan G. and Turner, Steve and van der Schee, Marc P. and Verhamme, Katia M. and Maitland-van der Zee, Anke H. (2017) Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. PHARMACOGENOMICS, 18 (10). pp. 931-943. ISSN 1462-2416, 1744-8042
Full text not available from this repository. (Request a copy)Abstract
Aim: International collaboration is needed to enable large-scale pharmacogenomics studies in childhood asthma. Here, we describe the design of the Pharmacogenomics in Childhood Asthma (PiCA) consortium. Materials & methods: Investigators of each study participating in PiCA provided data on the study characteristics by answering an online questionnaire. Results: A total of 21 studies, including 14,227 children/young persons (58% male), from 12 different countries are currently enrolled in the PiCA consortium. Fifty six percent of the patients are Caucasians. In total, 7619 were inhaled corticosteroid users. Among patients from 13 studies with available data on asthma exacerbations, a third reported exacerbations despite inhaled corticosteroid use. In the future pharmacogenomics studies within the consortium, the pharmacogenomics analyses will be performed separately in each center and the results will be meta-analyzed. Conclusion: PiCA is a valuable platform to perform pharmacogenetics studies within a multiethnic pediatric asthma population.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INHALED CORTICOSTEROIDS; GENOMEWIDE ASSOCIATION; SEVERE EXACERBATIONS; PACMAN COHORT; REPORTED USE; CHILDREN; THERAPY; RISK; POLYMORPHISM; PREDICTORS; asthma; children; consortium; genetics; pharmacogenomics; treatment |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Kinder- und Jugendmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:16 |
| Last Modified: | 28 Feb 2019 12:25 |
| URI: | https://pred.uni-regensburg.de/id/eprint/1601 |
Actions (login required)
 |
View Item |
